Exercise of Options and Total Voting Rights

RNS Number : 1897A

Destiny Pharma PLC

31 January 2022

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 Exercise of Options and Total Voting Rights

Brighton, United Kingdom - 31 January 2022 -   Destiny Pharma (AIM: DEST) a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces  that it has issued 466,177 new ordinary shares of 1 pence each in the capital of the Company (the "New Ordinary Shares") following an exercise of share options by a former employee.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 4 February 2022 ("Admission").

Following Admission, the Company will have a total of 60,338,098 Ordinary Shares in issue. Shareholders may use this figure of 60,338,098 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

[phone] 

[e-mail]  

Optimum Strategic Communications 

Mary Clark  / Manel Mateus / Vici Rabbetts

[phone]

[e-mail]  

finnCap Ltd  (Nominated Adviser and Joint Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane, Corporate Broking

[phone]

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of  C. difficile  infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

For further information on the company, please visit  https://www.destinypharma.com

 

END

 

 

TVRUAUSRUAUAOAR